Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06680947
PHASE2

A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

View on ClinicalTrials.gov

Summary

This study will assess the effcacy and safety of 610 as an adjunctive therapy in adult subjects with severe eosinophilic asthma.

Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIb, Effcacy and Safety Study of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Therapy in Adult Subjects With Severe Asthma

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

225

Start Date

2024-12-20

Completion Date

2027-09

Last Updated

2026-01-29

Healthy Volunteers

No

Conditions

Interventions

DRUG

610

Subcutaneously injection.

DRUG

610

Subcutaneously injection.

DRUG

Placebo

Subcutaneously injection.

Locations (1)

Shanghai General Hospital

Shanghai, Shanghai Municipality, China